Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

116.95 +1.03 (+0.89%)
Streaming Delayed Price Updated: 1:47 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
PTCT Earnings Beat but Sales Drop 4%
Via The Motley Fool
Topics Earnings
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium
Via Stocktwits
Earnings Outlook For Novartis
 
Via Benzinga
Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report
Via Stocktwits
How Do Investors Really Feel About Novartis?
 
Via Benzinga
Monte Rosa (GLUE) Q2 Revenue Jumps 394%
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Schrödinger (SDGR) Q2 2025 Earnings Transcript
Via The Motley Fool
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal
The company is focused on treatments for forms of muscular dystrophy. 
Via Investor's Business Daily
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon. 
Via Benzinga
Topics Economy Government World Trade
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability
NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors. 
Via Chartmill
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues. 
Via Investor's Business Daily
Topics Death Workforce
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run
Via The Motley Fool
Topics ETFs World Trade
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Via The Motley Fool
Topics Government World Trade
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Potentially Undervalued Stock With Strong Fundamentals
NOVARTIS AG (NYSE:NVS) presents a value opportunity with strong profitability, financial health, and reasonable growth, trading below industry and market valuations. 
Via Chartmill
Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses
The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone. 
Via Investor's Business Daily
Topics Government Stocks
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales. 
Via Benzinga
Earnings Scheduled For July 17, 2025
 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
Divi’s Labs Shares Dip After Patent Loss: SEBI RA Recommends Buy On Dips
The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto. 
Via Stocktwits
Topics Intellectual Property
This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It?
Via The Motley Fool
Topics ETFs
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.